ArticleImmunity & ageing : I & A2025
Differential immune profiles in elderly patients with non-severe versus severe SARS-CoV-2 omicron variant infection: dysregulation of antibody responses and B-cell subsets.
Article in Immunity & ageing : I & A, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundElderly individuals represent a population at disproportionate risk for severe outcomes following SARS-CoV-2 infection. The humoral immune response critically controls viral replication and disease progression. However, the antibody responses and B-cell subsets to mutant strains of SARS-CoV-2 in elderly patients have not yet been fully elucidated. This study aims to elucidate the humoral immune response and B-cell subsets distribution in elderly patients infected with SARS-CoV-2 Omicron variant, thereby providing insights for identifying prognostic biomarkers and developing therapeutic strategies.
methodsUsing enzyme-linked immunosorbent assays and pseudotyped virus neutralization assays, we determined plasma levels of RBD-specific IgA, IgM, IgG, and neutralizing antibodies from 46 elderly patients with SARS-CoV-2 Omicron variant infection within the first two weeks post-symptom onset (PSO). Using a multicolor flow cytometry approach, we analyze the frequencies of different B-cell subsets and assess the functional characterization of B-cells.
resultIn elderly non-severe patients, SARS-CoV-2 RBD-specific antibody levels (IgA, IgM, and IgG) increased progressively within the first two weeks post-symptom onset (PSO). In contrast, severe patients exhibited lower initial antibody levels during 0-3 days PSO but experienced a transient surge (11-fold for IgA, 12-fold for IgM, and 48-fold for IgG) during 4-7 days PSO, which was followed by a decline between 8-14 days. Despite this early elevated response in severe patients, both groups ultimately demonstrated generally weak neutralizing activity against the SARS-CoV-2 Omicron variant. Both elderly patient groups exhibited an higher proportion of plasmablasts (PB). Among these, class-switched IgM
conclusionElderly individuals generate RBD-specific and neutralizing antibody responses after SARS-CoV-2 Omicron variant infection, which correlate significantly with disease severity and infection duration. Clinically, these findings highlight the potential utility of antibody kinetics as prognostic biomarkers for stratifying elderly patients at high risk of severe outcomes, thereby informing tailored intervention strategies and vaccine booster optimization. Furthermore, SARS-CoV-2 Omicron variant infection affects the distribution of B-cell subsets, which may predict the long-term immune reconstitution capacity post-recovery. Notably, elderly patients exhibit pronounced PB expansion, a response pattern that facilitates antibody class-switching to enhance antiviral immunity. Such expansion represents a key immunologic feature in elderly patients with SARS-CoV-2 Omicron variant infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.